/image/Fesoterodine-Fumarate.jpg "Fesoterodine (Fumarate) - Synthetic Route")
Fesoterodine is an antimuscarinic drug developed to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012. Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.
Process for the preparation of fesoterodine fumarate; Dwivedi, Shriprakash Dhar; Prasad, Ashok; Jain, Kuldeep Natwarlal; Assignee Cadila Healthcare Limited, India; 2013; Patent Information; Sep 06, 2013; IN 2010MU02373; A
Dirat, Olivier; Bibb, Andrew J.; Burns, Colin M.; Checksfield, Graham D.; Dillon, Barry R.; Field, Stuart E.; Fussell, Steven J.; Green, Stuart P.; Mason, Clive; Mathew, Jinu; Mathew, Suju; Moses, Ian B.; Nikiforov, Petar I.; Pettman, Alan J.; Susanne, Flavien; Organic Process Research & Development; Volume 15; Issue 5; Pages 1010-1017; Journal; 2011
New uses of diisopropylamine derivatives; Mills, Ian William; Scholfield, David Peter; Assignee Pfizer Limited, UK; 2010; Patent Information; Feb 18, 2010; WO 2010018484 A1
Raman, Jayaraman Venkat; Patel, Samir; Thakor, Indrajit; Parekh, Viral; Ladani, Mahesh; Patil, Chetan; Patel, Ronak; Raval, Prashant. Process for the preparation of fesoterodine. Assignee Alembic Pharmaceuticals Limited, India. IN 2012MU00062. (2013).
Chen, Ming; Hartwig, John F. Iridium-Catalyzed Enantioselective Allylic Substitution of Enol Silanes from Vinylogous Esters and Amides. Journal of the American Chemical Society. Volume 137. Issue 43. Pages 13972-13979. 2015.
Charugundla, Kishore; Kumar, Udhaya; Kumar, Neela Praveen; Pradhan, Nitin Sharadchandra. Process for the preparation of fesoterodine fumarate using solid state forms of fesoterodine intermediates. Assignee Actavis Group PTC Ehf, Iceland. US 20110124903. (2011).
Piccolo, Oreste; Giannini, Elios; Bigini, Laura; Gianolli, Edoardo; Vigo, Daniele. Process for the preparation of 2-(3-N,N-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol and its derivatives. Assignee Cambrex Profarmaco Milano S.r.l., Italy. WO 2014012832. (2014).
Desai, Sanjay Jagdish; Patel, Kalpesh Mahendrabhai; Shah, Aakash Maheshkumar; Pada, Ranjit Shardulbhai; Makwana, Hitesh Manubhai. Method for preparation of fesoterodine and its pharmaceutically acceptable salts for treatment of urinary incontinence. Assignee Intas Pharmaceuticals Limited, India. WO 2011141932. (2011).
Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Raghuram, Suraparaju; Sarma, Peri Seetha Rama. Preparation of muscarinic receptor antagonist isobutyric acid 2[(R)-3-diisopropylamino-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester hydrogen fumarate and derivatives. Assignee MSN Laboratories Limited, India. WO 2012098560. (2012).
Jain, Rajesh; Rao, Siripragada Mahender; Rao, Jagadeeshwar R.; Madada, Chandra Rao. Process for the preparation of fesoterodine and intermediates. Assignee Panacea Biotec Ltd., India. WO 2011158257. (2011).
